HW
SUPN icon

Hancock Whitney’s Supernus Pharmaceuticals SUPN Stock Holding History

Hancock Whitney’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,885
Closed -$201K – 648
2024
Q1 		$201K Buy
+5,885
New +$175K 0.01% 622
2023
Q2 		– Sell
-5,758
Closed -$209K – 661
2023
Q1 		$209K Sell
5,758
-263
-4% -$10.1K 0.01% 613
2022
Q4 		$214K Sell
6,021
-24
-0.4% -$834 0.01% 594
2022
Q3 		$204K Buy
+6,045
New +$197K 0.01% 588
2022
Q2 		– Sell
-6,242
Closed -$201K – 673
2022
Q1 		$201K Buy
+6,242
New +$191K 0.01% 669
2019
Q4 		– Sell
-11,815
Closed -$325K – 864
2019
Q3 		$325K Sell
11,815
-1,176
-9% -$34.8K 0.01% 677
2019
Q2 		$430K Buy
12,991
+212
+2% +$7.26K 0.01% 648
2019
Q1 		$448K Sell
12,779
-7,365
-37% -$274K 0.01% 647
2018
Q4 		$669K Sell
20,144
-2,942
-13% -$127K 0.02% 502
2018
Q3 		$1.16M Buy
23,086
+14,615
+173% +$722K 0.03% 454
2018
Q2 		$507K Buy
+8,471
New +$439K 0.02% 426

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Hancock Whitney's SUPN Position: Q2 2024 in Review

Hancock Whitney sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 5,885 shares — an estimated $201K sold.

Hancock Whitney first reported a position in SUPN in Q2 2018 and held it in 11 quarters. The position peaked at $1.16M in Q3 2018. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

  • Hancock Whitney reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Hancock Whitney sold 5,885 Supernus Pharmaceuticals shares in Q2 2024, an estimated $201K.
  • Hancock Whitney first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 11 quarters.
  • Hancock Whitney's Supernus Pharmaceuticals position peaked at $1.16M in Q3 2018.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on Hancock Whitney's 13F filing for Q2 2024, filed 13 Aug 2024.